EBTATE – Patient Worthy

stevepb / Pixabay

The FDA Approves the Investigational Drug EBTATE for Neuroendocrine Tumors

Post author:Rose Duesterwald
Post published:March 15, 2021
Post category:Neuroendocrine Tumor

Molecular Targeting Technologies (MTTI), a radiopharmaceutical company, announced through Biospace that the FDA has given its approval for MTTI to move forward with a Phase 1 clinical trial to study…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More